Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Publisher
International Journal of Neuropsychopharmacology(1)
Pharmacogenomics Journal(1)
Psychopharmacology(1)
Origen
scopus(3)
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
ArticleAbstract: Background: The characterization of the first episode of psychosis and how it should be treated arePalabras claves:Antipsychotic, first episode psychosis, pharmacovigilance, polytherapy, psychotropic drugs, SchizophreniaAutores:Adrián LLerena, Aguilar E.J., Albacete A., Alonso-Solís A., Amoretti S., Baeza I., Balanzá-Martínez V., Bernardo M., Bioque M., Bobes J., Bulbena A., Butjosa A., Cabrera B., Castro-Fornieles J., Contreras F., Corripio I., Cuesta M.J., Díaz-Caneja M.C., Escartí M.J., García Bernardo E., García-Portilla M.P., Gassó P., González I., González-Pinto A., Grasa E., Hernandez M., Ibáñez Á., Lafuente A., Landín-Romero R., Lobo A., Mané A., Mas S., Mezquida G., Modrego F., Morales-Muñoz I., Parellada M., Rodriguez-Jimenez R., Ruiz P., Saiz-Ruiz J., Sánchez-Torres A.M., Sarró S., Segarra R., Tapia-Casellas C., Torrent C., Vieta E., Zabala Rabadán A.Fuentes:scopusPharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes
ArticleAbstract: This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symPalabras claves:Autores:Adrián LLerena, Aguilar E.J., Albacete A., Alonso-Solís A., Arbej J., Baeza I., Balanzá-Martínez V., Balbuena A., Barcones F., Bernardo E.G., Bernardo M., Bioque M., Bobes J., Butjosa A., Cabrera B., Contreras F., Corripio I., Cuadrado A.I., Cuesta M.J., de la Serna E., Echevarría R.S., García-Portilla M.P., Gassó P., González-Pinto A., Grasa E., Hernandez M., Lafuente A., Landín-Romero R., Lobo A., Mané A., Martínez-Cengotitabengoa M., Mas S., Meseguer A., Mezquida G., Morales-Muñoz I., Olmeda M.S., Parellada M., Rabadán A.Z., Rodie J.U., Rodriguez-Jimenez R., Saiz-Ruiz J., Sanjuán J., Sarró S., Torrent C., Vieta E.Fuentes:scopusThe usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis
ArticleAbstract: Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present studyPalabras claves:Drug level, Efficacy, First-episode psychosis, Olanzapine, pharmacokinetics, Therapeutic drug monitoring, Weight gainAutores:Adrián LLerena, Alonso-Solís A., Amoretti S., Anmella G., Aragón Z., Arnaiz J.A., Baeza I., Balanzá-Martínez V., Bernardo M., Bioque M., Bobes J., Butjosa A., Casanovas F., Castro-Fornieles J., Colomer L., Contreras F., Corripio I., Cuesta M.J., de la Serna E., De-la-Cámara C., Díaz-Caneja M.C., Durán-Cutilla M., Fares-Otero N.E., Fraguas D., García S., García-Portilla M.P., García-Rizo C., González-Pinto A., Grasa E., Gutiérrez-Fraile M., Hernandez-Viadel M., Ibáñez Á., Lobo A., López P., Mané A., Mas S., Mezquida G., Moltó M.D., Moreno C., Pomarol-Clotet E., Ribeiro M., Rodrigues-Silva C., Rodriguez-Jimenez R., Saiz C., Saíz J., SanAgustin D., Sarró S., Saz P., Torra M., Usall J., Vieta E., Zabala Rabadán A.Fuentes:scopus